Effectiveness of a Single Fosfomycin Dosage Compared to a Five-Day Ciprofloxacin Course in patients with simple Urinary Tract Infection
Abstract
Background: Treating simple diseases like uncomplicated urinary tract infection (UTIs) have become a challenge for physicians due to multi- drug resistance and genetic variations globally as well as in our local population.
Aim: To determine the effectiveness of a single fosfomycin (3g) dose in comparison to a 05 daysciprofloxacin (1g)doseamong patients suffering fromuncomplicated urinary tract infection.
Methods: This was randomized controlled trial (RCT) with 128 patients enrolled and divided into two groups. Group A received fosfomycin 3mg for 1 day, and group B received ciprofloxacin 1g for 5 days. The data was analyzed in SPSS 25 Version.
Results: Patients in group A had an average age of 43.5±9.4 years, while those in group B had an average age of 46.2 ± 7.9. With a statistically significant p-value of 0.028, fosfomycin group A exhibits substantially better efficacy, i.e., 87.5%, than ciprofloxacin group B, i.e., 71.9%.The study compared Fosfomycin and Ciprofloxacin's efficacy across age groups, marital statuses, and symptoms durations. Fosfomycin was found to be more effective in patients aged 20-40 and married, but not in those aged 40-60, unmarried, or with longer symptoms.
Practical Implication: Short duration of medicine, and more effectiveness in treating patients make it better choice for treating UTIs.
Conclusion: The outcomes of the Fosfomycin treatment were comparable to those of the ciprofloxacin treatment, even though it was only a single dose course and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 128 participants or records.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.